Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/ pharmacodynamic model with simulated endocardial vegetations

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3174-3180

  Hall, Ashley D ^a   Steed, Molly E ^a   Arias, Cesar A ^c,d   Murray, Barbara E ^c   Rybak, Michael J ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d Molecular Genetics and Antimicrobial Resistance Unit   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; LINEZOLID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM COLONY; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG EXPOSURE; DRUG MEGADOSE; ENDOCARDIUM; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; EVALUATION; HALF LIFE TIME; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SIMULATION; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; DAPTOMYCIN; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; VANCOMYCIN;

EID: 84861135687     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06439-11     Document Type: Article

References (40)

1. Akins RL, Rybak MJ. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459. (Pubitemid 32105280)
2. Akins RL, Rybak MJ. 2000. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob. Agents Chemother. 44:1925-1929. (Pubitemid 30422950)
3. Anastasiou DM, Thorne GM, Luperchio SA, Alder JD. 2006. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int. J. Antimicrob. Agents 28:385-388. (Pubitemid 44636192)
4. Arias CA, et al. 2011. Genetic basis for in vivo daptomycin resistance in enterococci. N. Engl. J. Med. 365:892-900.
5. Arias CA, et al. 2007. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin. Infect. Dis. 45:1343-1346. (Pubitemid 351411911)
6. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249. (Pubitemid 44527494)
7. Boucher HW, Sakoulas G. 2007. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 45:601-608. (Pubitemid 47328642)
8. Bowker KE, Noel AR, MacGowan AP. 2009. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. J. Antimicrob. Chemother. 64: 1044-1051.
9. Cha R, Grucz RG, Jr, Rybak MJ. 2003. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob. Agents Chemother. 47:1598-1603. (Pubitemid 36548543)
10. Cha R, Rybak MJ. 2003. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn. Microbiol. Infect. Dis. 47:539-546. (Pubitemid 37338519)
11. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement, CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Crank CW, et al. 2010. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study. Clin. Ther. 32:1713-1719.
13. Cunha BA, Mickail N, Eisenstein L. 2007. E. faecalis vancomycinsensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung 36: 456-461. (Pubitemid 350086682)
14. Dubrovskaya Y, Kubin C, Furuya E. 2008. Daptomycin compared to linezolid for primary treatment of vancomycin-resistant Enterococcus bacteremia (VREB). Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC. http://www.icaac.org/.
15. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323. (Pubitemid 36368592)
16. Figueroa DA, et al. 2009. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin. Infect. Dis. 49:177-180.
17. Gaffney M, McKinnon P, Mohr J, Zervos MJ. 2009. Clinical experience with daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia. Abstr. 49th Annu. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009. http://www.icaac.org/.
18. Gallagher JC, et al. 2009. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 29:792-799.
19. Gee T, et al. 2001. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother. 45:1843-1846. (Pubitemid 32466358)
20. Grim SA, Hong I, Freeman J, Edwards C, Clark NM. 2009. Daptomycin for the treatment of vancomycin-resistant enterococcal infections. J. Antimicrob. Chemother. 63:414-416.
21. Hjalmarson K, Craven D, Golan Y. 2008. The use of daptomycin in vancomycin-resistant Enterococcus (VRE) bacteremia: a single center experience. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC. http://www.icaac.org/.
22. Johnson AP, Mushtaq S, Warner M, Livermore DM. 2004. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int. J. Antimicrob. Agents 24:315-319. (Pubitemid 39369474)
23. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. 2011. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin. Infect. Dis. 52:228-234.
24. Kullar R, et al. 2011. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 31:527-536.
25. Lamp KC, Rybak MJ. 1993. Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium. Antimicrob. Agents Chemother. 37:605-609. (Pubitemid 23072611)
26. Long JK, Choueiri TK, Hall GS, Avery RK, Sekeres MA. 2005. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin. Proc. 80:1215-1216. (Pubitemid 41233359)
27. Louie A, et al. 2001. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 45:845-851. (Pubitemid 32182035)
28. Marion C, Kennedy L, High K. 2008. Daptomycin or linezolid in the treatment of vancomycin-resistant enterococcal bacteremia in neutropenic cancer patients. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC. http://www.icaac.org/.
29. Mave V, Garcia-Diaz J, Islam T, Hasbun R. 2009. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J. Antimicrob. Chemother. 64:175-180.
30. McGee B, et al. 2009. Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 53:3981-3984.
31. McKinnell JA, et al. 2011. Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents. Epidemiol. Infect. 139:1342-1350.
32. Mohr JF, Friedrich LV, Yankelev S, Lamp KC. 2009. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int. J. Antimicrob. Agents 33: 543-548.
33. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. 2009. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann. Pharmacother. 43:1211-1219.
34. Munoz-Price LS, Lolans K, Quinn JP. 2005. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin. Infect. Dis. 41:565-566. (Pubitemid 41099656)
35. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. 2011. Genetic basis for daptomycin resistance in enterococci. Antimicrob. Agents Chemother. 55:3345-3356.
36. Pfizer, Inc. 2010. Zyvox package insert. Pfizer, Inc., New York, NY.
37. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. 2007. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J. Infect. 54:567-571. (Pubitemid 46731225)
38. Sader HS, Jones RN. 2009. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn. Microbiol. Infect. Dis. 65:158-162.
39. Safdar N, Andes D, Craig WA. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68. (Pubitemid 38040177)
40. Steed ME, et al. 2011. Characterizing vancomycin-resistant enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 55:4748-4754.